These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37328353)

  • 1. RSV: A vaccine is coming, time to educate providers.
    Ciemins EL; Gillen A; Tallam M
    Vaccine; 2023 Jul; 41(32):4636-4638. PubMed ID: 37328353
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
    Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
    Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
    Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
    Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).
    Phan SI; Chen Z; Xu P; Li Z; Gao X; Foster SL; Teng MN; Tripp RA; Sakamoto K; He B
    Vaccine; 2014 May; 32(25):3050-7. PubMed ID: 24717150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care physicians' perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults.
    Hurley LP; Allison MA; Kim L; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen KE; Poser S; Lindley MC; Kempe A
    Vaccine; 2019 Jan; 37(4):565-570. PubMed ID: 30598385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4
    Schneider-Ohrum K; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; Cheng LI; O'Day T; Cayatte C
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.
    Gerretsen HE; Capone S; Vitelli A; Reyes LS; Thompson A; Jones C; Green CA; Pollard AJ; Sande CJ
    Vaccine; 2018 Nov; 36(46):6988-6994. PubMed ID: 30318168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist-driven respiratory syncytial virus prophylaxis stewardship service in a neonatal intensive care unit.
    Rostas SE; McPherson C
    Am J Health Syst Pharm; 2016 Dec; 73(24):2089-2094. PubMed ID: 27919877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
    Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
    Malkin E; Yogev R; Abughali N; Sliman J; Wang CK; Zuo F; Yang CF; Eickhoff M; Esser MT; Tang RS; Dubovsky F
    PLoS One; 2013; 8(10):e77104. PubMed ID: 24204744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus: prospects for new and emerging therapeutics.
    Jorquera PA; Tripp RA
    Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    Walsh EE; Pérez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; Rämet M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B;
    N Engl J Med; 2023 Apr; 388(16):1465-1477. PubMed ID: 37018468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
    N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
    Maier C; Fuchs J; Irrgang P; Wißing MH; Beyerlein J; Tenbusch M; Lapuente D
    Front Immunol; 2022; 13():920256. PubMed ID: 36003372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
    Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
    N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.